secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001558370-23-001897
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium Q4 record net revenue $129.6M; FY22 adj. EBITDA $266.0M, reaffirms 2023 guidance
--------------------------------------------------------------------------------

- Q4 product revenue $129.6M (up from $27.4M YoY); GAAP net loss $(7.2)M vs $(25.0)M YoY.
- FY22 product revenue $463.9M (up 68% YoY); non-GAAP adjusted EPS $3.96 vs $2.58.
- Completed BDSI integration with $85M run-rate synergies; resolved all 27 opioid lawsuits.
- Board authorized $100M share repurchase program in Jan 2023; cash balance $173.7M at year-end.
- Reaffirms 2023 guidance: product revenue $565-580M, adjusted EBITDA $355-370M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000155837023001897/0001558370-23-001897-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000155837023001897/coll-20230223x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-001897

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer